UK markets open in 2 hours 16 minutes
  • NIKKEI 225

    27,562.89
    -407.33 (-1.46%)
     
  • HANG SENG

    25,027.16
    -59.27 (-0.24%)
     
  • CRUDE OIL

    72.08
    +0.43 (+0.60%)
     
  • GOLD FUTURES

    1,806.10
    +6.30 (+0.35%)
     
  • DOW

    35,058.52
    -85.79 (-0.24%)
     
  • BTC-GBP

    28,631.58
    +1,973.69 (+7.40%)
     
  • CMC Crypto 200

    929.61
    +53.38 (+6.09%)
     
  • ^IXIC

    14,660.58
    -180.14 (-1.21%)
     
  • ^FTAS

    4,010.29
    -15.70 (-0.39%)
     

Global Cachexia Pipeline Report 2021: Comprehensive Insights About 22+ Companies and Respective Pipeline Drugs

·5-min read

Dublin, June 30, 2021 (GLOBE NEWSWIRE) -- The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Cachexia - Pipeline Insight, 2021" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

Cachexia Emerging Drugs Chapters

This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cachexia Emerging Drugs

GCWB 204: Green Cross Wellbeing

GCWB 204 (BST 204), a purified ginseng extract with reinforced ginsenosides Rh2 and Rg3. Green Cross Wellbeing is developing the drug as oral capsule in Phase II clinical studies for the treatment of cancer cachexia.

Ponsegromab: Pfizer

Ponsegromab (formerly PF-06946860) is subcutaneous, monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1). The drug is in Phase I clinical developmental studies for the treatment of Cachexia.

Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cachexia

There are approx. 22+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. Phase II include, Green Cross Wellbeing.

Phases

This report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

Cachexia Report Insights

  • Cachexia Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Cachexia Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cachexia drugs?

  • How many Cachexia drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Cachexia and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Incyte Corporation

  • Green Cross Wellbeing

  • AEterna Zentaris

  • AVEO Oncology

  • AstraZeneca

  • Endevica Bio

  • Actimed Therapeutics

  • Creative Medical Technology Holdings

  • Ildong Pharmaceutical

  • Immuneering

Key Products

  • Ruxolitinib

  • GCWB 204

  • Macimorelin

  • AV 380

  • ART 2713

  • TCMCB-07

  • ACM-002

Research programme: amniotic stem cell therapies

  • ID 11917

Research programme: cancer therapeutics

Key Topics Covered:

Introduction

Executive Summary

Cachexia: Overview

  • Causes

  • Mechanism of Action

  • Signs and Symptoms

  • Diagnosis

  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type

  • Assessment by Stage and Product Type

  • Assessment by Route of Administration

  • Assessment by Stage and Route of Administration

  • Assessment by Molecule Type

  • Assessment by Stage and Molecule Type

Cachexia - Analytical Perspective

In-depth Commercial Assessment

  • Cachexia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Cachexia Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis

  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug name: Company name

  • Product Description

  • Research and Development

  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

GCWB 204: Green Cross Wellbeing

  • Product Description

  • Research and Development

  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

Ponsegromab: Pfizer

  • Product Description

  • Research and Development

  • Product Development Activities

Preclinical/Discovery Stage Products

  • Comparative Analysis

TCMCB-07: Endevica Bio

  • Product Description

  • Research and Development

  • Product Development Activities

Inactive Products

  • Comparative Analysis

Cachexia Key Companies

Cachexia Key Products

Cachexia- Unmet Needs

Cachexia- Market Drivers and Barriers

Cachexia- Future Perspectives and Conclusion

Cachexia Analyst Views

Cachexia Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hcx7w5

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting